"I went from feeling fine to wondering when I should schedule bypass surgery."

Ask gastroenterologist and clinical researcher Dr. Tim Ritter and he jokes that he's not overweight, just "under height" — it's how he's always handled his one visible risk factor.

On paper, Tim looked low risk. No diabetes. No smoking. Native LDL around 70. Normal blood pressure for most of his adult life. A perfect cardiac CT and MR angiogram more than 20 years ago. For decades he focused on cancers, inflammatory bowel disease and the patients in his rapidly growing national research network — not his own heart. He figured, "I'll die like everyone else someday, but not from my arteries."

Then subtle changes started showing up. About three years ago, while working hard to lose weight with a GLP-1 medication, Tim noticed his blood pressure creeping into the 145/90 range. Like many doctors, he tried to treat himself first. It didn't work.

He finally handed the wheel to his internist, who dialed in his blood pressure and ordered a coronary calcium score just to be thorough. Tim almost skipped it. With his history of pristine scans and good labs, it felt like a formality. The result was a shock: a calcium score in the thousands.

"I went from feeling fine to wondering when I should schedule bypass surgery," Tim recalls. The number alone was terrifying. A nuclear stress test showed no classic ischemia, but did reveal transient ischemic dilation — a red flag that can point to multivessel or left-main disease. Because Tim had no symptoms, his cardiologist didn't want to rush him to the cath lab. Instead, he referred Tim to ClearCardio to look under the hood with more precision.

At ClearCardio, Tim underwent advanced CCTA with AI plaque analysis. The scan confirmed significant plaque burden, especially in his right-dominant coronary system, but no critical blockages. He had real coronary artery disease, despite great numbers and no warning signs, yet he was not an immediate surgical case. That opened the door to a different path: aggressive, root-cause prevention.

Working with ClearCardio, Tim intensified his cholesterol regimen from a modest statin and baby aspirin to a high-potency statin, Repatha, and then Plavix instead of aspirin. He added low-dose colchicine to target arterial inflammation, not just cholesterol. He continued GLP-1 therapy and focused on weight loss and lifestyle.

Here's where the precision of CCTA + AI mattered most. On his second scan, even with excellent labs, Tim's plaque volume had increased. In traditional cardiology, no one would have known; his numbers alone looked like a win. With ClearCardio's tools, the team could see that, in his body, the first regimen wasn't enough.

They adjusted. Repatha drove his LDL down to near-zero. Colchicine calmed the inflammation "fertilizer" inside the artery wall. On his third scan, for the first time, the story changed: his total plaque volume and high-risk components began to trend down.

For Tim, who spends his life running clinical trials and bringing tomorrow's medicine to today's patients, this was powerful. He wasn't guessing. He had hard evidence that the disease he never expected to have is now moving in the right direction. Today Tim feels well, his blood pressure is controlled, his LDL is single-digits, and his plaque is finally shrinking under watchful, data-driven eyes.

His message to those with no classic risk factors: you can't assume great numbers equal a healthy heart. But if you're willing to look early and treat deeply, you can find hidden plaque, change your plan, and watch the disease reverse in real time.